Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
d-Cycloserine is a broad-spectrum antibiotic and a structural analogue of the amino acid D-alanine. It is primarily used as a second-line agent in the treatment of multidrug-resistant tuberculosis (MDR-TB), often in combination with other antitubercular drugs. Its antibacterial activity results from inhibition of bacterial cell wall synthesis by competitively inhibiting two key enzymes involved in peptidoglycan biosynthesis—L-alanine racemase and D-alanyl-D-alanine synthetase—thereby preventing formation and cross-linking of peptidoglycan chains essential for bacterial cell wall integrity[1][5][6]. In addition to its antimicrobial use, d-cycloserine has been investigated as an adjunctive therapy for certain psychiatric conditions due to its partial agonist activity at the NMDA receptor glycine site, which may enhance neural plasticity[5][6]. It is administered orally and rapidly absorbed. Common side effects include neuropsychiatric symptoms such as dizziness, headache, mood changes, seizures, and allergic reactions; it should be used with caution in patients with renal impairment or pre-existing neurological disorders[9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on d-cycloserine.